On October 1, 2021, the World Health Organization issued a report on the 22nd Model Essential Medicines List (EML). The new list added four new drugs for cancer, including enzalutamide, but also illustrated the role of high prices as a barrier to access. The WHO noted in a press release that: “A group of antibodies that enhance the immune response to tumour cells, called PD-1 / PD-L1 immune-checkpoint inhibitors, were not recommended for listing for the treatment of a number of lung cancers, despite being effective, mainly because of their exceedingly high price and concerns that they are difficult to manage in low-resourced health systems.Read More →